Qiagen (NYSE:QGEN) Releases FY 2025 Earnings Guidance

Qiagen (NYSE:QGEN - Get Free Report) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided EPS guidance of 2.350- for the period, compared to the consensus EPS estimate of 2.300. The company issued revenue guidance of $2.1 billion-, compared to the consensus revenue estimate of $2.0 billion.

Qiagen Stock Performance

Shares of NYSE QGEN traded up $0.53 during trading hours on Thursday, reaching $44.91. The stock had a trading volume of 1,554,902 shares, compared to its average volume of 1,159,697. The company has a market cap of $9.98 billion, a price-to-earnings ratio of 125.04, a PEG ratio of 2.39 and a beta of 0.67. Qiagen has a twelve month low of $37.63 and a twelve month high of $49.30. The business's fifty day moving average is $41.49 and its two-hundred day moving average is $41.84. The company has a debt-to-equity ratio of 0.38, a current ratio of 3.61 and a quick ratio of 3.09.

Qiagen (NYSE:QGEN - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $0.55 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.50 by $0.05. Qiagen had a net margin of 4.23% and a return on equity of 13.92%. The company had revenue of $483.46 million during the quarter, compared to analysts' expectations of $465.66 million. During the same quarter in the prior year, the company posted $0.44 EPS. The business's revenue was up 5.2% on a year-over-year basis. As a group, research analysts expect that Qiagen will post 2.26 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. Baird R W downgraded Qiagen from a "strong-buy" rating to a "hold" rating in a report on Wednesday, February 19th. UBS Group lowered their price target on Qiagen from $50.00 to $48.00 and set a "neutral" rating on the stock in a research report on Friday, February 7th. Redburn Atlantic lowered Qiagen from a "buy" rating to a "neutral" rating in a research note on Friday, April 4th. Robert W. Baird boosted their target price on shares of Qiagen from $42.00 to $43.00 and gave the company a "neutral" rating in a research note on Monday, April 21st. Finally, Wall Street Zen raised shares of Qiagen from a "buy" rating to a "strong-buy" rating in a report on Thursday, May 15th. Seven analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $48.42.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Qiagen stock. United Services Automobile Association bought a new stake in Qiagen (NYSE:QGEN - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 5,946 shares of the company's stock, valued at approximately $239,000. 70.00% of the stock is owned by hedge funds and other institutional investors.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.